It's possible that study was three-armed, Keytruda, Keytruda+leronlimab and placebo. At some point prior to a phase1a trial the FDA would want to see a four phase study with one of the phases being leronlimab alone to sort out any safety issues. The best way to start that off is with the initial pre-clinical study.